Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 256

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 256
---
spectus entitled “Cautionary Statement Regarding Forward-Looking Statements.”

| 129 |

In considering the
Business Combination, FutureTech’s board of directors gave considerable weight to the following factors:

Due Diligence.
FutureTech’s management conducted a due diligence review of Longevity and review of the Targets that included an industry analysis,
an analysis of the existing business model of Longevity and the Targets and historical and projected financial results. FutureTech’s
management, including its directors and advisors, have many years of experience in both operational management and investment and financial
management and analysis and, in the opinion of FutureTech’s Board, were suitably qualified to conduct the due diligence, reviews
and other analyses required in connection with the search for a business combination partner. A detailed description of the experience
of FutureTech’s executive officers and directors is included in the section of this proxy statement/prospectus entitled “Management of FutureTech—Directors and Executive Officers.”

Large market opportunity. According to the United Nations Population Division, the global population of people ages
65 and above has doubled in the last 25 years, from 392 million in 1997 to 758 million in 2021. Longevity is focused on longevity-related
products and services a market with increasing demands from the growing global aging population. The company has the potential to integrate
advancement of new technologies across therapeutics, monitoring and digital health into the future platform;

Commercial Potential of Candidate Products. Through the acquisition of Aegeria and Ceravast, Longevity will have a series of candidate products
under development, including AAT101 for soft tissue reconstruction, Aureva Pulse for ischemic stroke, Reflow RVO for retinal veinocclusion
and a biosynthetic cornea;

| ● | LBI-101 is designed as an off-the-shelf substitute for autologous fat grafting and a potential tissue 
 replacement solution for treatment of soft tissue defects, reconstructive surgery and aesthetics;     |

| ● | LBI-201 is a therapeutic ultrasound device that is designed to be used in combination with tissue plasminogen                             
 activator during the acute phase of ischemic stroke to break-up blood clots and restore blood flows to the ischemic regions of the brain; 
 and                                                                                                                                       |

| ● | LBI-001 is designed to treat the venous blood clot in the retinal vein by combining the intravenous administration 
 of microspheres with non-invasive therapeutic ultrasound delivered across the closed inferior eyelid,